Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy.
Sagen
Jørn V
JV
Section of Pediatrics, Department of Clinical Medicine, University of Bergen, N-5021 Bergen, Norway.
Raeder
Helge
H
Hathout
Eba
E
Shehadeh
Naim
N
Gudmundsson
Kolbeinn
K
Baevre
Halvor
H
Abuelo
Dianne
D
Phornphutkul
Chanika
C
Molnes
Janne
J
Bell
Graeme I
GI
Gloyn
Anna L
AL
Hattersley
Andrew T
AT
Molven
Anders
A
Søvik
Oddmund
O
Njølstad
Pål R
PR
D019943:Amino Acid Substitution; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000151:congenital* / Q000188:drug therapy / Q000235:genetics*; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007231:Infant, Newborn; D008297:Male; D010375:Pedigree; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics*; D021122:Protein Subunits / Q000235:genetics; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D000099161:Kcnj11 Channel
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D024661:Potassium Channels, Inwardly Rectifying; D021122:Protein Subunits; D013453:Sulfonylurea Compounds; D000099161:Kcnj11 Channel